CN110997723B - Cd38调节抗体 - Google Patents

Cd38调节抗体 Download PDF

Info

Publication number
CN110997723B
CN110997723B CN201880049994.2A CN201880049994A CN110997723B CN 110997723 B CN110997723 B CN 110997723B CN 201880049994 A CN201880049994 A CN 201880049994A CN 110997723 B CN110997723 B CN 110997723B
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
seq
acd38
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880049994.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110997723A (zh
Inventor
帕斯卡·梅希尔
安妮·古比耶
凯文·莫尔德
妮娜·艾斯勒
约瑟芬·萨利姆
西蒙尼·菲利斯托
贝特里兹·古耶内切亚·科尔佐
赫曼塔·巴鲁
比安卡·普林兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Black Belt Medical Co ltd
Original Assignee
Black Belt Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Belt Medical Co ltd filed Critical Black Belt Medical Co ltd
Publication of CN110997723A publication Critical patent/CN110997723A/zh
Application granted granted Critical
Publication of CN110997723B publication Critical patent/CN110997723B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880049994.2A 2017-06-08 2018-06-08 Cd38调节抗体 Active CN110997723B (zh)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201762517149P 2017-06-08 2017-06-08
US201762517150P 2017-06-08 2017-06-08
US62/517,150 2017-06-08
US62/517,149 2017-06-08
US201762517734P 2017-06-09 2017-06-09
US201762517164P 2017-06-09 2017-06-09
US201762517740P 2017-06-09 2017-06-09
US201762517745P 2017-06-09 2017-06-09
US201762517753P 2017-06-09 2017-06-09
US201762517165P 2017-06-09 2017-06-09
US62/517,753 2017-06-09
US62/517,745 2017-06-09
US62/517,164 2017-06-09
US62/517,734 2017-06-09
US62/517,740 2017-06-09
US62/517,165 2017-06-09
US201762582666P 2017-11-07 2017-11-07
US201762582676P 2017-11-07 2017-11-07
US201762582653P 2017-11-07 2017-11-07
US201762582681P 2017-11-07 2017-11-07
US62/582,681 2017-11-07
US62/582,676 2017-11-07
US62/582,666 2017-11-07
US62/582,653 2017-11-07
PCT/EP2018/065243 WO2018224685A1 (en) 2017-06-08 2018-06-08 Cd38 modulating antibody

Publications (2)

Publication Number Publication Date
CN110997723A CN110997723A (zh) 2020-04-10
CN110997723B true CN110997723B (zh) 2023-09-26

Family

ID=62620847

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880049994.2A Active CN110997723B (zh) 2017-06-08 2018-06-08 Cd38调节抗体
CN201880049993.8A Active CN110997722B (zh) 2017-06-08 2018-06-08 Cd38调节抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880049993.8A Active CN110997722B (zh) 2017-06-08 2018-06-08 Cd38调节抗体

Country Status (8)

Country Link
US (3) US12161717B2 (cg-RX-API-DMAC7.html)
EP (2) EP3635002A1 (cg-RX-API-DMAC7.html)
JP (3) JP7237950B2 (cg-RX-API-DMAC7.html)
KR (3) KR102770106B1 (cg-RX-API-DMAC7.html)
CN (2) CN110997723B (cg-RX-API-DMAC7.html)
AU (3) AU2018280869B2 (cg-RX-API-DMAC7.html)
CA (2) CA3066553A1 (cg-RX-API-DMAC7.html)
WO (2) WO2018224683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018280869B2 (en) 2017-06-08 2025-01-02 Black Belt Therapeutics Limited CD38 modulating antibody
CA3073085A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 modulating antibody
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
BR112021014574A2 (pt) * 2019-01-23 2021-10-05 Encefa Competidores cd31 e usos dos mesmos
US12453738B2 (en) 2019-03-12 2025-10-28 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
JP7555953B2 (ja) * 2019-03-29 2024-09-25 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ３８に結合する操作されたバリアント抗体
WO2020205527A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
EP4211476A4 (en) * 2020-09-10 2024-11-13 CASI Pharmaceuticals, Inc. BLOOD SCREENING PROCEDURES
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218256A (zh) * 2005-03-23 2008-07-09 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
CN101626782A (zh) * 2006-12-01 2010-01-13 梅达雷克斯公司 结合cd22的人抗体及其用途
AU2011202520A1 (en) * 2002-10-17 2011-06-23 Genmab A/S Human monoclonal antibodies against CD20
JP2012504801A (ja) * 2008-10-06 2012-02-23 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア ミスフォールドタンパク質エピトープを予測するための方法およびシステム
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
CA2965745A1 (en) * 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
AU2016228249A1 (en) * 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
PL2511297T3 (pl) 2004-02-06 2015-08-31 Morphosys Ag Ludzkie przeciwciała anty-CD38 i ich zastosowania
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EP1872124A4 (en) * 2005-04-19 2008-06-11 Prediction Sciences Llc DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE
EP2799451A1 (en) * 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
AR055191A1 (es) 2005-10-12 2007-08-08 Morphosys Ag Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
WO2008074004A2 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
NZ596237A (en) 2006-12-27 2012-07-27 Dana Farber Cancer Inst Inc Compositions and methods for the treatment of infections and tumors
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2193146B1 (en) 2007-09-14 2016-05-25 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
EA026336B1 (ru) 2009-09-22 2017-03-31 Пробиоген Аг Клетка позвоночного или насекомого для продукции белка или липида, не содержащего фукозу или содержащего сниженное количество фукозы, и ее применения
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
KR20150131177A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. 항-CRTh2 항체 및 그의 용도
US10675352B2 (en) 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
CA2969214A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
US9951144B2 (en) 2015-04-08 2018-04-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD38
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
MY198560A (en) 2015-10-02 2023-09-05 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
AU2018280869B2 (en) 2017-06-08 2025-01-02 Black Belt Therapeutics Limited CD38 modulating antibody
EP4036116A4 (en) * 2019-09-27 2024-01-24 Nanjing GenScript Biotech Co., Ltd. ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011202520A1 (en) * 2002-10-17 2011-06-23 Genmab A/S Human monoclonal antibodies against CD20
CN101218256A (zh) * 2005-03-23 2008-07-09 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
AU2016228249A1 (en) * 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
CN101626782A (zh) * 2006-12-01 2010-01-13 梅达雷克斯公司 结合cd22的人抗体及其用途
JP2012504801A (ja) * 2008-10-06 2012-02-23 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア ミスフォールドタンパク質エピトープを予測するための方法およびシステム
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
CA2965745A1 (en) * 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Direct in Vitro Comparison ofDaratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984and Ab79;VAN BUEREN JEROEN LAMMERTS ET AL;《BLOOD》;第3474页 *
Immunomodulatory activity of lsatuximab;SRINIVASAN SRIMATHI S ET AL;《CANCER IMMUNOLOGY RESEARCH》;第26页 *
Immuno-targeting the multifunctional CD38 using nanobody;T. Li, et al.;《SCIENTIFIC REPORTS》;第1-11页 *
New developments in the treatment of multiple myelomabr /clinical utility of daratumumab;CIAN MCELLISTRIM ET AL;《BIOLOGICS: TARGETS AND THERAPY》;第31-43页 *
SAR650984,A Novel Humanized CD38-Targeting AntibodyDemonstrates Potent Antitumor Activity in Models of Multiple Myeloma and OtherCD38+ Hematologic Malignancies;J.DECKERT ET AL;《CLINICAL CANCER RESEARCH》;第4574-4583页 *
抗人CD38分子单克隆抗体生物学功能研究;温新宇等;《免疫学杂志》;第631-635页 *

Also Published As

Publication number Publication date
EP3635003A1 (en) 2020-04-15
KR20200021069A (ko) 2020-02-27
CN110997722B (zh) 2023-09-26
US20230103584A1 (en) 2023-04-06
KR102719065B1 (ko) 2024-10-17
CN110997722A (zh) 2020-04-10
AU2018280869B2 (en) 2025-01-02
EP3635002A1 (en) 2020-04-15
JP7237950B2 (ja) 2023-03-13
CA3066555A1 (en) 2018-12-13
WO2018224685A1 (en) 2018-12-13
AU2018280871A8 (en) 2020-01-30
JP7467584B2 (ja) 2024-04-15
KR102770106B1 (ko) 2025-02-21
KR20200021068A (ko) 2020-02-27
CA3066553A1 (en) 2018-12-13
AU2018280869A1 (en) 2020-01-16
US12343394B2 (en) 2025-07-01
JP2020522280A (ja) 2020-07-30
US20210277138A1 (en) 2021-09-09
JP7237951B2 (ja) 2023-03-13
JP2023030071A (ja) 2023-03-07
JP2020522281A (ja) 2020-07-30
NZ760448A (en) 2025-03-28
NZ760342A (en) 2025-03-28
CN110997723A (zh) 2020-04-10
WO2018224683A1 (en) 2018-12-13
US20250367286A1 (en) 2025-12-04
AU2025201908A1 (en) 2025-04-03
KR20250025514A (ko) 2025-02-21
US12161717B2 (en) 2024-12-10
AU2018280871A1 (en) 2020-01-16
AU2018280871B2 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
CN110997723B (zh) Cd38调节抗体
JP7596447B2 (ja) Ｃｄ３８調節抗体
CN111032086B (zh) Cd38抗体
CN111032693B (zh) Cd38调节抗体
US11542338B2 (en) CD38 modulating antibody
KR20200019669A (ko) Cd38 조정 항체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant